Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Louisiana Leqvio Prior Auth | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield of LouisianaPolicy MA-246

    Inclisiran (Leqvio) Coverage

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy MA-246 alerts

    Get alerted when Policy MA-246 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Medicare Advantage policy governs eligibility and prior authorization for inclisiran (Leqvio) in members with familial hypercholesterolemia, hypercholesterolemia, or atherosclerotic cardiovascular disease. Coverage requires available benefits and satisfaction of the policy's medical-necessity criteria.

    Policy Summary
    PayerBlue Cross Blue Shield of Louisiana
    PolicyInclisiran (Leqvio) Coverage
    Policy CodePolicy MA-246
    Change TypeNew policy
    Effective DateJanuary 1, 2027
    Last ReviewOct 20, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document required statin or ezetimibe therapy, applicable patient-selection criteria, and a maximum-dose PCSK9 inhibitor trial when required.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    284 mgInitial dose
    3 monthsSecond dose
    Every 6 monthsMaintenance interval
    12 weeksPCSK9 trial
    J1306HCPCS code

    Coverage Criteria

    Initial Therapy

    Coverage eligibility for initial therapy requires ALL of the following criteria.

    ALL of the following

    • Patient is 18 years of age or older, except that patients with HoFH may be 12–17 years of age and patients with HeFH may be 12 years of age or older.
    • Patient is adherent to any medications required for therapy before receiving authorization for inclisiran (Leqvio).
    • Inclisiran (Leqvio) will not be used in combination with lomitapide (Juxtapid), evolocumab (Repatha), alirocumab (Praluent), evinacumab-dgnb (Evkeeza), or lerodalcibep-liga (Lerochol).
    • Inclisiran (Leqvio) will be used with a maximally tolerated statin in patients who are not statin intolerant.
    Policy Summary
    PayerBlue Cross Blue Shield of Louisiana
    PolicyInclisiran (Leqvio) Coverage
    Policy CodePolicy MA-246
    Change TypeNew policy
    Effective DateJanuary 1, 2027
    Last ReviewOct 20, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document required statin or ezetimibe therapy, applicable patient-selection criteria, and a maximum-dose PCSK9 inhibitor trial when required.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsPrior Authorization and DocumentationPolicy BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaRequired Step TherapyQuantity Limits and DosingSite of Care
    Inclisiran (Leqvio) will be dosed at 284 mg initially, at 3 months, and then every 6 months thereafter.
  1. ONE qualifying indication pathway

    • Patient meets the familial hypercholesterolemia without clinical ASCVD pathway.
    • Patient meets the clinical ASCVD pathway.
    • Patient meets the statin-intolerant hypercholesterolemia pathway.
    • Patient meets the familial hypercholesterolemia qualification pathway, including the HoFH pathway where applicable.
  2. FH Without Clinical ASCVD

    Patient must have FH without clinical ASCVD and meet at least one of the following treatment pathways.

    FH without clinical ASCVD

    • Patient has a diagnosis of familial hypercholesterolemia (FH) without clinical atherosclerotic cardiovascular disease, defined as a WHO/Dutch Lipid Clinic Network score greater than 8.
    • ONE of the following

      • LDL-C is not adequately controlled, meaning it remains above the applicable treatment goal of less than 70 mg/dL, with a high-intensity statin (rosuvastatin 20–40 mg or atorvastatin 40–80 mg) for at least 3 months.
      • LDL-C is not adequately controlled, meaning it remains above the applicable treatment goal of less than 70 mg/dL, with a maximally tolerated stable daily statin of any potency for at least 3 months, only when documentation shows that a high-intensity statin was not well tolerated.
      • Statin-intolerant FH pathway

        • LDL-C is not adequately controlled, meaning it remains above the applicable treatment goal of less than 70 mg/dL, due to statin intolerance.
        • Patient meets all criteria confirming statin intolerance, including inability to tolerate at least 2 different statins, confirmed intolerable statin-related adverse effects, and resolution or significant improvement of symptoms or biomarker changes after dose reduction or discontinuation.

    Clinical Atherosclerotic Cardiovascular Disease

    Patient must have clinical ASCVD and meet at least one of the following treatment pathways.

    Clinical ASCVD pathway

    • Patient has clinical atherosclerotic cardiovascular disease, with or without FH.
    • ONE of the following

      • LDL-C is not adequately controlled, meaning it remains above the treatment goal of less than 100 mg/dL for the patient's clinical risk category, with a high-intensity statin (rosuvastatin 20–40 mg or atorvastatin 40–80 mg) plus ezetimibe 10 mg daily for at least 3 months.
      • LDL-C is not adequately controlled, meaning it remains above the treatment goal of less than 100 mg/dL for the patient's clinical risk category, with a maximally tolerated stable daily statin of any potency plus ezetimibe 10 mg daily for at least 3 months, only when documentation shows that a high-intensity statin was not well tolerated.
      • Statin-intolerant ASCVD pathway

        • LDL-C is not adequately controlled due to statin intolerance, remaining above the treatment goal of less than 55 mg/dL for very high-risk individuals or less than 70 mg/dL for high-risk individuals.
        • Patient meets all criteria confirming statin intolerance.

    Statin-Intolerant Hypercholesterolemia

    Patient must meet ALL of the following criteria.

    ALL of the following

    • Patient has hypercholesterolemia not associated with FH or clinical ASCVD.
    • Patient has a baseline untreated LDL-C level greater than or equal to 190 mg/dL.
    • LDL-C is not adequately controlled, meaning it remains above the treatment goal of less than 100 mg/dL for the patient's clinical risk category, due to statin intolerance.
    • Patient meets all criteria confirming statin intolerance.

    Confirmed Statin Intolerance

    Patient must meet ALL of the following criteria confirming statin intolerance.

    ALL of the following

    • Patient was unable to tolerate at least 2 different statins. Inability to tolerate 1 statin is accepted only if the patient experienced rhabdomyolysis or clinically significant myonecrosis secondary to a statin. Rhabdomyolysis or myonecrosis means muscle pain, weakness, or tenderness with either acute renal failure or myoglobinuria and creatine kinase greater than or equal to 10 times the upper limit of normal, or creatine kinase greater than or equal to 10 times the upper limit of normal alone.
    • Intolerance was associated with confirmed, intolerable statin-related adverse effects, including skeletal-related muscle symptoms such as myopathy (muscle weakness) or myalgia (muscle aches, soreness, stiffness, or tenderness).
    • Symptoms or biomarker changes resolved or showed significant improvement after dose reduction or discontinuation.

    Familial Hypercholesterolemia Qualification

    Patient must meet ONE of the following familial hypercholesterolemia qualification pathways.

    ONE of the following

    • Genetic confirmation of 2 pathogenic variants at the LDLR, apo B, PCSK9, or LDLRAP1 gene locus.
    • Untreated LDL-C pathway

      • Untreated LDL-C is greater than 400 mg/dL. Untreated means before therapy with any antihyperlipidemic agent.
      • ONE of the following

        • Clinical manifestations of HoFH occurred before age 10 years, including cutaneous or tendon xanthomas, arcus cornea, tuberous xanthomas, or xanthelasma.
        • Both parents had untreated LDL-C or total cholesterol levels consistent with HeFH.
    • Treated LDL-C pathway

      • Treated LDL-C is greater than or equal to 300 mg/dL. Treated means after therapy with at least 1 antihyperlipidemic agent.
      • ONE of the following

        • Clinical manifestations of HoFH occurred before age 10 years, including cutaneous or tendon xanthomas, arcus cornea, tuberous xanthomas, or xanthelasma.
        • Both parents had untreated LDL-C or total cholesterol levels consistent with HeFH.

    HoFH Patient-Selection Criteria

    For the treated LDL-C HoFH pathway, patient must meet ALL of the following criteria.

    HoFH patient-selection criteria

    • Patient has a treated LDL-C level greater than or equal to 300 mg/dL. Treated means after therapy with at least 1 antihyperlipidemic agent, such as a statin, ezetimibe, PCSK9 inhibitor, evinacumab-dgnb, or lomitapide.
    • ONE of the following

      • Patient had clinical manifestations of homozygous familial hypercholesterolemia (HoFH) before age 10 years, including cutaneous xanthomas, tendon xanthomas, arcus cornea, tuberous xanthomas, or xanthelasma.
      • Both parents had untreated LDL-C levels or total cholesterol levels consistent with heterozygous familial hypercholesterolemia (HeFH). An example is untreated LDL-C greater than or equal to 190 mg/dL and/or untreated total cholesterol greater than 250 mg/dL in both parents. In digenic HoFH, one parent may have normal LDL-C levels and the other may have LDL-C levels consistent with HoFH.

    Required Lipid-Lowering Response or Genotype

    Patient must meet ONE of the following criteria.

    ONE of the following

    • PCSK9 inhibitor response pathway

      • Patient has tried a PCSK9 inhibitor for at least 12 continuous weeks at the FDA-approved maximum dose for the requested indication. Examples include evolocumab 140 mg every 2 weeks or 420 mg every 4 weeks, and alirocumab 150 mg every 2 weeks or 300 mg every 4 weeks.
      • After the maximum PCSK9 inhibitor dosing regimen, LDL-C remains above the applicable treatment goal listed in the patient-selection criteria for the requested indication.
    • Patient is known to have 2 LDL-receptor-negative alleles.

    Continuation Therapy

    Continuation therapy requires ALL of the following criteria.

    ALL of the following

    • Patient received initial authorization from the plan or provides documentation of authorization for an active course of treatment from a previous health plan.
    • Inclisiran (Leqvio) is dosed at 284 mg every 6 months.
    • Inclisiran (Leqvio) will not be used in combination with lomitapide (Juxtapid), evolocumab (Repatha), alirocumab (Praluent), evinacumab-dgnb (Evkeeza), or lerodalcibep-liga (Lerochol).
    • Patient has achieved clinically significant LDL-C lowering and is adherent to inclisiran (Leqvio).

    Blue Advantage does not cover investigational or experimental services, including drugs, devices, procedures, or services provided under the investigational arm of a clinical trial or study, unless coverage is mandated by the Centers for Medicare and Medicaid Services. Coverage is limited to routine services for Category A IDE studies and to Category B IDE devices and related services when not supplied by the trial sponsor. Approved IDE studies are posted on www.cms.gov/medicare/coverage/evidence.

    Inclisiran (Leqvio) must not be used in combination with lomitapide (Juxtapid), evolocumab (Repatha), alirocumab (Praluent), evinacumab-dgnb (Evkeeza), or lerodalcibep-liga (Lerochol).

    The hypercholesterolemia pathway applies only when the condition is not associated with familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease.

    Inclisiran (Leqvio) must not be used in combination with lomitapide (Juxtapid), evolocumab (Repatha), alirocumab (Praluent), evinacumab-dgnb (Evkeeza), or lerodalcibep-liga (Lerochol).

    Inclisiran (Leqvio) is not medically necessary when the member has not tried statin therapy plus ezetimibe 10 mg daily or does not meet the criteria for statin intolerance.

    The required prerequisite medications must have been tried and failed for at least 3 months before inclisiran (Leqvio) is considered medically necessary.

    Continued use of inclisiran (Leqvio) is not medically necessary when the patient has not achieved clinically significant LDL-C lowering or is not adherent to inclisiran (Leqvio).

    Inclisiran (Leqvio) is not medically necessary when the patient has not tried and failed 12 weeks of therapy with a PCSK9 inhibitor, such as evolocumab (Repatha) or alirocumab (Praluent).

    Coding and Clinical Thresholds

    CPTCPT
    No codesNo codes
    HCPCSHCPCS
    J1306J1306
    ICD-10 DiagnosisICD-10
    All Related DiagnosesAll Related Diagnoses
    LDL-C Treatment Goal
    High-risk LDL-C treatment goal<70 mg/dL
    Therapy durationAt least 3 months of high-intensity statin therapy
    Alternative therapyA maximally tolerated stable daily statin may be used when high-intensity statin intolerance is documented
    Very-High-Risk LDL-C Goal
    Very-high-risk LDL-C treatment goal<55 mg/dL
    High-risk comparison goal<70 mg/dL
    Treatment assessmentLDL-C must remain above the applicable risk-category goal
    FH Diagnostic Score
    FH diagnosis threshold without clinical ASCVD>8 points on the WHO/Dutch Lipid Clinic Network score
    Condition assessedFamilial hypercholesterolemia without clinical atherosclerotic cardiovascular disease
    Diagnostic frameworkWHO/Dutch Lipid Clinic Network criteria
    Rhabdomyolysis/Myonecrosis Threshold
    Creatine kinase threshold≥10 times the upper limit of normal
    Qualifying symptomsMuscle pain, weakness, or tenderness
    Additional qualifying findingsAcute renal failure or myoglobinuria may accompany the CK elevation
    Creatine Kinase Criterion
    Creatine kinase threshold≥10 times the upper limit of normal
    Clinical contextRhabdomyolysis or clinically significant myonecrosis secondary to a statin
    Single-statin exceptionOne statin may qualify when this severe muscle injury is documented
    Baseline Untreated LDL-C
    Baseline untreated LDL-C≥190 mg/dL
    Measurement statusBefore therapy with any antihyperlipidemic agent
    Applicable pathwayStatin-intolerant hypercholesterolemia
    LDL-C Treatment Goal
    LDL-C treatment goal<100 mg/dL
    Reason for remaining above goalStatin intolerance
    Risk assessmentGoal applies to the patient's clinical risk category
    HoFH Untreated LDL-C
    Untreated LDL-C threshold>400 mg/dL
    Applicable pathwayHomozygous familial hypercholesterolemia
    Definition of untreatedBefore therapy with any antihyperlipidemic agent
    Parental HeFH Lipid Threshold
    Parental untreated LDL-C example≥190 mg/dL in each parent
    Alternative parental measureTotal cholesterol >250 mg/dL in each parent
    Family history requirementBoth parents have lipid levels consistent with HeFH
    Treated LDL-C
    Treated LDL-C threshold≥300 mg/dL
    Definition of treatedAfter therapy with at least one antihyperlipidemic agent
    Applicable pathwayFamilial hypercholesterolemia qualification
    HoFH Treated LDL-C Criterion
    Treated LDL-C threshold≥300 mg/dL
    Required additional findingClinical HoFH manifestations before age 10 or qualifying parental lipid history
    Treatment statusMeasured after at least one antihyperlipidemic agent
    Parental HeFH Lipid Example
    Parental untreated LDL-C example≥190 mg/dL in both parents
    Parental total cholesterol example>250 mg/dL in both parents
    Alternative formulationUntreated LDL-C ≥190 mg/dL and/or untreated total cholesterol >250 mg/dL
    PCSK9 Inhibitor Trial
    Required PCSK9 inhibitor trialAt least 12 continuous weeks
    Dose requirementFDA-approved maximum dose for the requested indication
    ExamplesRepatha or Praluent at the applicable maximum dose
    Carotid Plaque Criterion
    Carotid plaque threshold≥50% stenosis
    Clinical categoryClinical atherosclerotic cardiovascular disease
    Qualifying findingDocumented carotid plaque
    Peripheral Arterial Disease Criterion
    Ankle-brachial index thresholdABI <0.90
    Clinical categoryAtherosclerotic peripheral arterial disease
    ASCVD classificationQualifies as clinical ASCVD when presumed atherosclerotic in origin
    WHO/Dutch FH Categories
    Definite FH>8 points
    Probable FH6–8 points
    Possible or unlikely FHPossible: 3–5 points; unlikely: <3 points
    LDL-C Component of Dutch Lipid Clinic Criteria
    LDL-C ≥330 mg/dL≥8.5 mmol/L; 8 points
    LDL-C 250–329 mg/dL6.5–8.4 mmol/L; 5 points
    LDL-C 190–249 or 155–189 mg/dL190–249: 5.0–6.4 mmol/L, 3 points; 155–189: 4.0–4.9 mmol/L, 1 point

    Prior Authorization and Documentation

    Prior Authorization

    Initial Authorization Criteria

    Request initial authorization for inclisiran (Leqvio) only when all applicable coverage criteria are documented. The patient must meet the age, adherence, noncombination, statin-use, dosing, indication, and treatment-response requirements.

    • Age 18 years or older, except HoFH patients ages 12–17 and HeFH patients age 12 or older.
    • Patient is adherent to medications required before inclisiran authorization.
    • Use with a maximally tolerated statin unless the patient meets the statin-intolerance criteria.
    • Dose: 284 mg initially, at 3 months, and every 6 months thereafter.
    Documentation Required

    Statin-Intolerant Hypercholesterolemia Authorization

    For statin-intolerant hypercholesterolemia, document the diagnosis, untreated baseline LDL-C, inadequate LDL-C control despite appropriate therapy, and the applicable statin-intolerance pathway.

    • Hypercholesterolemia must not be associated with familial hypercholesterolemia or clinical ASCVD.
    • Baseline untreated LDL-C must be at least 190 mg/dL.
    • LDL-C must remain above the applicable goal of less than 100 mg/dL due to statin intolerance.
    • Document the required statin and ezetimibe therapy or the applicable high-intensity-statin intolerance exception.
    Documentation Required

    Familial Hypercholesterolemia Authorization

    For familial hypercholesterolemia authorization, submit evidence supporting the applicable FH or HoFH pathway and demonstrate that LDL-C remains inadequately controlled despite the required treatment.

    • Document genetic confirmation, qualifying untreated or treated LDL-C levels, clinical manifestations, and/or family history as applicable.
    • The applicable LDL-C and age criteria must be satisfied.
    • Include treatment history and the current LDL-C level relative to the required treatment goal.

    Unsupported block type: prior_auth

    Prior Authorization

    Continuation Authorization

    For continuation authorization, document that the patient was previously authorized or is continuing an active course from a prior health plan and remains on the required regimen.

    • Prior plan authorization or active-course documentation is required when applicable.
    • Inclisiran dose must be 284 mg every 6 months.
    • Do not use with lomitapide, evolocumab, alirocumab, evinacumab-dgnb, or lerodalcibep-liga.
    • Document clinically significant LDL-C lowering and adherence to inclisiran.
    Prior Authorization

    Prior Authorization Required for All Listed Codes

    Prior authorization is required for every code listed in this policy before services are rendered.

    • Submit the authorization request and supporting clinical documentation for all listed codes.
    • Coverage may be at risk when authorization is not obtained in advance.
    Step Therapy

    Required Statin and Ezetimibe Therapy

    Before requesting inclisiran, document the required statin therapy and ezetimibe therapy unless the policy’s statin-intolerance pathway applies.

    • Use a high-intensity statin or maximally tolerated stable daily statin as required by the applicable indication.
    • For the applicable hypercholesterolemia pathway, use ezetimibe 10 mg daily with the statin for at least 3 months.
    • Document adherence to prerequisite medications.
    Documentation Required

    Statin and Ezetimibe Prerequisites

    Submit documentation of the statin and ezetimibe prerequisites, including drug, dose, duration, adherence, LDL-C response, and reason for discontinuation or modification when applicable.

    • High-intensity statin examples: rosuvastatin 20–40 mg or atorvastatin 40–80 mg.
    • Ezetimibe requirement: 10 mg daily.
    • The policy generally requires at least 3 months of prerequisite therapy.
    Step Therapy

    PCSK9 Inhibitor Step Requirement

    A PCSK9 inhibitor step is required before inclisiran for the applicable initial-authorization pathways.

    • Document at least 12 continuous weeks of therapy with a PCSK9 inhibitor at the FDA-approved maximum dose for the requested indication.
    • Examples include evolocumab 140 mg every 2 weeks or 420 mg every 4 weeks, and alirocumab 150 mg every 2 weeks or 300 mg every 4 weeks.
    • Submit the post-treatment LDL-C level and show that it remains above the applicable goal.
    Documentation Required

    Evidence of Statin Intolerance

    When statin intolerance is claimed, document either intolerance to at least two different statins or the qualifying exception for intolerance to one statin.

    • The one-statin exception requires rhabdomyolysis or clinically significant myonecrosis with muscle symptoms and qualifying creatine kinase findings.
    • For rhabdomyolysis or myonecrosis, document CK at least 10 times the upper limit of normal, with acute renal failure or myoglobinuria or qualifying CK elevation alone as specified.
    • If a high-intensity statin was not tolerated, document the high-intensity statin trial and the applicable alternative maximally tolerated regimen.
    Documentation Required

    Document Statin Trials and Adverse Effects

    Submit detailed records of attempted statins and the adverse effects associated with each trial. The record must show that symptoms or biomarker abnormalities improved after dose reduction or discontinuation.

    • Identify each statin, dose, dates of use, and outcome.
    • Describe confirmed intolerable skeletal muscle adverse effects, including myopathy or myalgia.
    • Document symptom or biomarker resolution or significant improvement after dose decrease or discontinuation.
    Documentation Required

    Submit Lipid Measurements and Treatment Response

    Submit lipid measurements and treatment-response documentation sufficient to establish the diagnosis, baseline untreated LDL-C, current LDL-C, treatment history, and applicable risk-category goal.

    • For non-FH, non-ASCVD hypercholesterolemia, document untreated LDL-C of at least 190 mg/dL.
    • Document that current LDL-C remains above the applicable goal despite the required therapy or because of statin intolerance.
    • Include dates, medication status, adherence, and the patient’s clinical risk category.
    Documentation Required

    Familial Hypercholesterolemia Evidence

    Familial hypercholesterolemia requests require evidence supporting the specific FH or HoFH pathway used for selection.

    • Genetic pathway: two pathogenic variants in LDLR, APOB, PCSK9, or LDLRAP1.
    • Untreated LDL-C pathway: LDL-C greater than 400 mg/dL plus qualifying HoFH manifestations before age 10 or parental lipid evidence consistent with HeFH.
    • Treated LDL-C pathway: treated LDL-C at least 300 mg/dL plus qualifying early HoFH manifestations or parental untreated lipid evidence.
    Documentation Required

    FH Lipid, Family, and Clinical Documentation

    Document the lipid, family-history, and clinical findings that establish FH or HoFH, including whether LDL-C values are untreated or treated.

    • Clinical manifestations may include cutaneous or tendon xanthomas, arcus cornea, tuberous xanthomas, or xanthelasma.
    • For parental evidence, document both parents’ untreated LDL-C or total cholesterol levels consistent with HeFH; an example is LDL-C at least 190 mg/dL and/or total cholesterol greater than 250 mg/dL.
    • Explain any digenic presentation when one parent has normal LDL-C and the other has LDL-C consistent with HoFH.
    Documentation Required

    Document PCSK9 Trial and Response

    For the PCSK9 pathway, document the product, dose, administration schedule, continuous treatment duration, and LDL-C result after the maximum-dose regimen.

    • The trial must be at the FDA-approved maximum dose for the requested indication and last at least 12 continuous weeks.
    • Document that LDL-C remains above the applicable treatment goal.
    • Use the genotype pathway instead when the patient is known to have two LDL-receptor-negative alleles.
    Documentation Required

    Continuation Documentation

    For continuation requests, submit the prior authorization or active-course evidence, current dose and schedule, adherence records, and objective evidence of clinically significant LDL-C lowering.

    • Document authorization from the current plan or the previous health plan when transitioning.
    • Confirm inclisiran 284 mg every 6 months.
    • Confirm that prohibited combination therapy is not being used.
    Prior Authorization

    Transition Authorization Documentation

    When a member changes health plans during an ongoing course of treatment, submit documentation of the previous plan’s authorization and the active course of treatment.

    • Blue Advantage may honor the prior authorization for the same service and same type of in-network benefit for a 90-day transition period.
    • The service must otherwise be covered under the Blue Advantage health plan.
    • Documentation must be provided by the member or provider.
    Denial Risk

    Investigational Use Exclusion

    Investigational or experimental services, drugs, devices, procedures, and biological products are not covered except as required by applicable CMS rules. Inclisiran is investigational when patient-selection criteria are not met, except where the policy identifies the service as not medically necessary.

    • Coverage is limited to applicable routine services for Category A IDE studies and qualifying Category B IDE devices and related services when not supplied by the trial sponsor.
    • Clinical-trial investigational-arm services are excluded unless mandated by CMS.
    Prior Authorization

    Benefit and Medical-Necessity Requirement

    Coverage is available only when benefits are present under the member’s contract and the policy’s medical-necessity criteria and guidelines are met.

    • Verify benefit availability before submitting the request.
    • The service must be clinically appropriate, effective, and consistent with nationally accepted standards of medical practice.
    Denial Risk

    Prohibited Combination Therapy

    Do not administer inclisiran in combination with lomitapide, evolocumab, alirocumab, evinacumab-dgnb, or lerodalcibep-liga.

    • Prohibited combinations include Juxtapid, Repatha, Praluent, Evkeeza, and Lerochol.
    • Confirm the medication list and treatment plan before authorization and each continuation request.
    Denial Risk

    Insufficient Statin Intolerance Documentation

    Authorization may be denied when the record does not adequately establish statin intolerance.

    • Document intolerance to at least two different statins, unless the qualifying one-statin rhabdomyolysis or clinically significant myonecrosis exception applies.
    • Include the adverse effects, doses, dates, objective findings when applicable, and improvement after dose reduction or discontinuation.
    Denial Risk

    Hypercholesterolemia Criteria Not Met

    Authorization may be denied when the hypercholesterolemia pathway is not met or the required lipid and treatment-response evidence is absent.

    • The diagnosis must be hypercholesterolemia not associated with FH or clinical ASCVD.
    • Untreated baseline LDL-C must be at least 190 mg/dL.
    • Current LDL-C must remain above the applicable goal because of statin intolerance or despite the required therapy.
    Denial Risk

    Familial Hypercholesterolemia Criteria Not Met

    Authorization may be denied when the submitted record does not establish the applicable familial hypercholesterolemia or HoFH criteria.

    • Provide qualifying genetic, untreated or treated LDL-C, clinical, and family-history evidence.
    • The submitted evidence must match one of the policy’s defined FH pathways and include the required age, lipid, and treatment details.
    Denial Risk

    Statin Plus Ezetimibe Trial Required

    Inclisiran is considered not medically necessary when the patient has not tried statin therapy plus ezetimibe 10 mg daily or does not meet the policy’s statin-intolerance criteria.

    • Document the required statin and ezetimibe trials or the complete statin-intolerance exception.
    • A request without the required prerequisite or intolerance documentation may be denied.
    Denial Risk

    Three-Month Prerequisite Requirement

    Inclisiran is considered not medically necessary when required prerequisite medications have not been tried and failed for at least 3 months.

    • Document at least 3 months of the applicable statin, maximally tolerated statin, and ezetimibe regimen.
    • Include adherence, dates, doses, and treatment response.
    Denial Risk

    Insufficient LDL-C Response or Nonadherence

    Continuation may be denied when the patient has not achieved clinically significant LDL-C lowering or is not adherent to inclisiran.

    • Submit objective follow-up LDL-C measurements.
    • Document administration dates and adherence to the every-6-month schedule.
    Denial Risk

    Required PCSK9 Trial Not Completed

    Inclisiran is considered not medically necessary when the patient has not tried and failed the required 12-week PCSK9 inhibitor course.

    • Document at least 12 continuous weeks at the FDA-approved maximum dose for the requested indication.
    • Submit the post-trial LDL-C level showing it remains above the applicable goal, unless the qualifying genotype pathway applies.
    Denial Risk

    Patient-Selection Criteria Not Met

    Inclisiran is considered investigational when patient-selection criteria are not met, except for circumstances separately identified by the policy as not medically necessary.

    • Confirm that the diagnosis, age, lipid values, treatment history, statin-intolerance evidence when applicable, and response or genotype pathway are all satisfied.
    • Requests outside the defined selection criteria may not receive coverage.
    Denial Risk

    Medical Necessity Must Be Established

    Coverage may be denied when the service does not meet the plan’s medical-necessity definition, including clinical appropriateness, effectiveness, accepted standards of practice, and the applicable benefit terms.

    • The service must be appropriate in type, frequency, extent, level of care, site, and duration.
    • The service must not be primarily for convenience and must not be more costly than an equally effective alternative.
    Prior Authorization

    Prior Authorization and Coverage Risk

    All codes listed in this policy require prior authorization. Failure to obtain authorization before treatment creates coverage and payment risk.

    • Submit the complete clinical record before services are provided.
    • Authorization does not override contract exclusions, benefit limitations, or other coverage requirements.

    Policy Background

    Inclisiran (Leqvio) is considered for patients with familial hypercholesterolemia, hypercholesterolemia, or atherosclerotic cardiovascular disease when LDL-C is not adequately controlled with specified statin-based therapy. The policy distinguishes FH, statin intolerance, and clinical ASCVD and applies pathway-specific LDL-C treatment thresholds and prerequisite therapy requirements.

    Definitions

    Familial Hypercholesterolemia
    DefinitionFH without clinical ASCVD is defined by a WHO/Dutch Lipid Clinic Network score >8
    Clinical statusNo clinical atherosclerotic cardiovascular disease
    Scoring basisThe score incorporates family history, clinical history, physical findings, cholesterol levels, and DNA analysis
    Rhabdomyolysis or Clinically Significant Myonecrosis
    Core definitionMuscle breakdown with muscle pain, weakness, or tenderness
    Laboratory thresholdCreatine kinase ≥10 times the upper limit of normal
    Additional findingAcute renal failure or myoglobinuria may be present
    Statin Intolerance
    Statins generally requiredUnable to tolerate at least 2 different statins
    Qualifying adverse effectsConfirmed, intolerable skeletal-muscle symptoms, including myopathy or myalgia
    Response after stopping or reducing therapySymptoms or biomarker changes resolved or significantly improved
    Rhabdomyolysis/Myonecrosis Clinical Definition
    SymptomsMuscle pain, weakness, or tenderness
    Creatine kinase≥10 times the upper limit of normal
    Possible accompanying findingAcute renal failure or myoglobinuria
    Statin-Related Adverse Effects
    MyopathyMuscle weakness
    MyalgiaMuscle aches, soreness, stiffness, or tenderness
    ClassificationThese are confirmed, intolerable statin-related skeletal-muscle symptoms
    Untreated LDL-C
    Untreated LDL-CLDL-C measured before therapy with any antihyperlipidemic agent
    Applicable contextUsed in HoFH qualification
    Example threshold>400 mg/dL in one HoFH pathway
    Clinical Manifestations of HoFH
    Cutaneous findingsCutaneous xanthomas or tuberous xanthomas
    Tendon and ocular findingsTendon xanthomas or arcus cornea
    Additional findingXanthelasma
    Treated LDL-C
    Treated LDL-CLDL-C measured after therapy with at least one antihyperlipidemic agent
    Examples of therapyStatins, ezetimibe, PCSK9 inhibitors, evinacumab-dgnb, or lomitapide
    Example criterionTreated LDL-C ≥300 mg/dL in an HoFH pathway
    Primary Hyperlipidemia
    DefinitionElevated LDL-C not due to a secondary cause
    Policy exclusionsNot associated with established cardiovascular disease, HeFH, or HoFH
    Alternative termsCombined hyperlipidemia, pure primary hypercholesterolemia, dyslipidemia, or increased/elevated LDL-C
    Clinical ASCVD
    Coronary conditionsMyocardial infarction, acute coronary syndrome, angina, or coronary revascularization
    Cerebrovascular and peripheral diseaseTransient ischemic attack, ischemic stroke, or atherosclerotic PAD with ABI <0.90
    Other qualifying diseaseClinically significant coronary atherosclerosis, renal atherosclerosis, atherosclerotic aortic aneurysm, or carotid plaque with ≥50% stenosis
    Treated LDL-C
    Measurement definitionLDL-C measured after therapy with at least one antihyperlipidemic agent
    Therapy examplesStatins, ezetimibe, PCSK9 inhibitors, evinacumab-dgnb, or lomitapide
    Policy useUsed in familial hypercholesterolemia and HoFH qualification
    Clinical ASCVD
    Acute coronary diseaseAcute coronary syndrome or history of myocardial infarction
    Other clinical eventsStable or unstable angina, coronary or arterial revascularization, stroke, or transient ischemic attack
    Peripheral diseasePeripheral artery disease presumed to be atherosclerotic in origin
    Subclinical Atherosclerosis
    DefinitionSignificant atherosclerotic plaque in an asymptomatic patient
    Detection methodsCoronary or chest CT, cardiac CT coronary angiography, carotid ultrasound or angiography, abnormal ABI, or peripheral arterial angiography
    Calcium scoring clarificationCalcium scoring alone is not indicative of ASCVD
    Premature Coronary or Vascular Disease
    MenBefore age 55 years
    WomenBefore age 60 years
    Condition coveredPremature coronary or vascular disease
    ODYSSEY ALTERNATIVE Statin Intolerance
    Number of statinsUnable to take at least 2 different statins
    ReasonMuscle-related adverse effects
    Dose requirementOne statin was administered at the lowest approved starting dose
    Investigational Treatment or Service
    Basic definitionA treatment, procedure, drug, device, or biological product whose effectiveness has not been clearly tested
    Practice statusNot incorporated into standard medical practice
    Assessment factorsFDA approval, need for further studies, reliable scientific evidence, technology evaluation, peer-reviewed literature, expert consensus, and federal regulations
    Medical Necessity
    PurposeServices or treatment a prudent provider would provide to prevent, evaluate, diagnose, or treat illness, injury, disease, or symptoms
    Clinical standardsMust comply with nationally accepted standards and be clinically appropriate and effective
    Cost and convenienceMust not be primarily for comfort or convenience or more costly than an equally effective alternative

    Initial Therapy Criteria

    Initial Inclisiran Therapy

    Coverage eligibility is considered when ALL applicable general requirements are met and the patient satisfies at least ONE qualifying diagnosis and LDL-C-treatment pathway.

    General initial requirements

    • Qualifying diagnosis pathway

      • FH without clinical ASCVD: Patient has FH without clinical ASCVD, defined by a WHO/Dutch Lipid Clinic Network score greater than 8, and meets an applicable statin-treatment or confirmed statin-intolerance pathway.Score >8; LDL-C goal <70 mg/dL
      • Clinical ASCVD: Patient has clinical ASCVD, with or without FH, and LDL-C remains above goal after the applicable statin-plus-ezetimibe or confirmed statin-intolerance pathway.Applicable goal <55, <70, or <100 mg/dL depending on the stated risk pathway
      • Statin-intolerant hypercholesterolemia: Patient has hypercholesterolemia not associated with FH or clinical ASCVD, baseline untreated LDL-C ≥190 mg/dL, LDL-C above the treatment goal because of statin intolerance, and confirmed statin intolerance.Untreated LDL-C ≥190 mg/dL; treatment goal <100 mg/dL
      • Familial hypercholesterolemia: Patient meets one qualifying FH pathway, including genetic confirmation, untreated LDL-C >400 mg/dL with qualifying HoFH history, or treated LDL-C ≥300 mg/dL with qualifying HoFH history.Untreated LDL-C >400 mg/dL or treated LDL-C ≥300 mg/dL

    Leqvio Initial Therapy

    Initial Leqvio therapy requires the applicable patient-selection criteria and ONE of the following response or genotype pathways.

    Lipid-lowering response or genotype

    • PCSK9 inhibitor trial and response: Patient has tried a PCSK9 inhibitor for at least 12 continuous weeks at the FDA-approved maximum dose for the requested indication, and LDL-C remains above the applicable treatment goal.≥12 continuous weeks at the FDA-approved maximum dose
    • LDL-receptor genotype: Patient is known to have two LDL-receptor-negative alleles.Two LDL-receptor-negative alleles

    Continuation Criteria

    Leqvio Continuation Therapy

    Patient must meet criteria I, II, III, and IV.

    Leqvio continuation criteria

    • I. Authorization: Patient has received initial authorization from the plan or has provided documentation of authorization for an active course of treatment from a previous health plan.
    • II. Dosing: Inclisiran is dosed at 284 mg every 6 months.284 mg every 6 months
    • III. Prohibited combination therapy: Inclisiran is not used in combination with lomitapide, evolocumab, alirocumab, evinacumab-dgnb, or lerodalcibep-liga.
    • IV. Response and adherence: Patient has achieved clinically significant LDL-C lowering and is adherent to inclisiran.

    Required Step Therapy

    StepRequired therapyDurationRequirement to advance
    1High-intensity statin therapy: rosuvastatin 20–40 mg or atorvastatin 40–80 mg. A maximally tolerated stable daily statin of any potency may substitute only when documentation shows that a high-intensity statin was not well tolerated.At least 3 monthsLDL-C remains above the applicable treatment goal.
    StepRequired therapyDurationRequirement to advance
    2High-intensity statin therapy plus ezetimibe 10 mg daily. A maximally tolerated stable daily statin of any potency plus ezetimibe 10 mg daily may substitute only when documentation shows that a high-intensity statin was not well tolerated.At least 3 monthsLDL-C remains above the applicable treatment goal.
    StepRequired therapyDurationRequirement to advance
    1Try statin therapy plus ezetimibe 10 mg daily, or meet the policy’s statin-intolerance criteria. Complete all required prerequisite medication trials.At least 3 monthsRequired prerequisite medications have been tried and failed.
    StepRequired therapyDurationRequirement to advance
    2Try a PCSK9 inhibitor at the FDA-approved maximum dose for the requested indication. Examples include evolocumab (Repatha) or alirocumab (Praluent).At least 12 continuous weeksLDL-C remains above the applicable treatment goal after the maximum-dose regimen.

    Quantity Limits and Dosing

    Inclisiran Dosing
    Initial dose284 mg
    Second doseAt 3 months
    Maintenance scheduleEvery 6 months thereafter
    Leqvio Dosing
    Dose284 mg
    Initial scheduleAdminister initially and again at 3 months
    Ongoing scheduleThen every 6 months
    Leqvio Administration Schedule
    Administration routeSubcutaneous injection
    Dose schedule284 mg initially, again at 3 months, and then every 6 months
    Site of administrationShould be administered by a healthcare professional

    Site of Care

    Billing Rule

    Administer inclisiran through a healthcare professional

    Inclisiran should be administered by a healthcare professional, in the office setting.